Introduction {#sec1-1}
============

Colorectal cancer is the most common malignancy of the gastrointestinal tract (Ciombor et al., 2015). Unfortunately, despite of rapid developments in the interventional radiology, surgery, regional and systemic therapy colorectal cancer is still the third most common cause of cancer-related deaths in the United States (Ciombor et al., 2015; Compton et al., 2000). Moreover after the adjuvant treatment of stage III cancer, metastatic disease develops more than half of these patients (Ciombor et al., 2015). In addition, despite the increase of overall survival with the more frequent use of the current targeting agents such as bevacizumab, cetuximab, panitimumab, and regorafenib in the metastatic disease, 5-years survival rate is still significantly below the hope expected (Ciombor et al., 2015).

In actual studies, prognostic and predictive features of different biomarkers, which produce a wide array of molecules such as preoperative carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), N-RAS, K-RAS, BRAF and microRNA, was to investigate in colorectal cancer patients (Ciombor et al., 2015; Loupakis et al., 2015).

Still the most important prognostic indicator in colorectal cancer TNM staging which was mainly based on three components including tumor penetration into the bowel wall (T), presence of nodal involvement (N), and metastasis (M) (Compton et al., 2000). In clinical practice while adjuvant treatment is recommended for stage III disease, stage II is recommended only in the presence of poor prognostic factors which are T4 stage, lymph node sampling of less than 12, clinical intestinal obstruction or perforation, poor histologic grade, and lymphovascular and perineural invasion (Ciombor et al., 2015; Compton et al., 2000; Loupakis et al., 2015). Uric acid is a last product in circle of nucleotide metabolism, which indicates process of nucleic acids catabolism along with free purine nucleotides, hypoxanthine and xanthine. With our previous knowledge, uric acid is most important molecule because of the antioxidant feature (Ames et al. 1981). However, the relationship between serum UA and cancer is not still clear as well as studies on this topic are very limited in the English literature (Fini et al., 2012). Conversely the theoretical explanation that increased serum UA levels might be protective against cancer due to its antioxidant properties, some studies reported that hyperuricemia increases cancer prevalence in mankind as well as rises up mortality among cancer patients (Ames et al. 1981; Fini et al., 2012; Tanriverdi et al., 2014). Despite these findings, a study of the literature on the relation between increased serum UA and colorectal cancer prognosis has not been reached.

In this study, we aimed to investigated whether the serum UA level's effects of cancer-related events in stage II and III colorectal cancer patients.

Materials and Methods {#sec1-2}
=====================

In this cross-sectional study, the medical records of 198 patients with colorectal adenocarcinoma, whom diagnosis proven as histologically between 2006 and 2015 were searched retrospectively, and a total of 150 stage II and III patients with no exclusion criteria were included in the study.

Date of diagnosis, age, gender, smoking habit, weight loss within the past three months, disease stage, histological type of tumor, tumor diameter, area(s) of metastasis at the first recurrence, neoadjuvant and adjuvant treatment options of all patients were recorded.

Patients with history of diabetes mellitus, metabolic syndrome, hypertension, rheumatologic diseases, hematological malignancies, alcoholism, gout, previously chemotherapy, and/or radiotherapy applications; patients who had acute coronary syndrome or cerebrovascular diseases within the past 6 months; patients on medication for hyperuricemia and hypertension; and patients whose serum UA level or other study related data were not available in the records were excluded from the study.

Serum UA levels of the patients that measured at the time of diagnosis were recorded, and the patients were stratified into quartiles according to serum UA levels.

Blood samples for laboratory analyses were drawn following an 8- to 12-h fasting. Measurements of serum UA and lactate dehydrogenase (LDH) levels were done using the "Abbott/Aeroset system (™)" device. Hemoglobin level (Hb;), leukocyte (Leu;) and platelet counts were the other variables of the study measured by ABX-PENTRA 120 DX® Hematology Analyzer (ABX Diagnostics, France). In addition, preoperative CEA and CA19-9 were recorded.

The data are expressed as the mean ± standard deviation or the median and interquartile range (25- 75%). Statistical methods such as the Kolmogorov-Smirnov test, the independent Student's t test, the Mann-Whitney U test, the Chi-square test, Fisher's test, the Kruskal-Wallis test were used for analyses of data. Additionally, univariate and multivariate analyses, multiple logistic regression method for identify independent risk factors, and Kaplan--Meier curves for disease-free survival analyses were used. Statistical significance level was set as P\<0.05.

Results {#sec1-3}
=======

Mean serum uric acid level of all patients was determined as 6.97±2.87 mg/dL (range, 3.1-12.4). Among the patients, the majority was males (68%), smokers (67%), patients who had lost more than 10 kilos in the past 3 months (54%), tumor grade II (57%), tumors located in the left colon and recto-sigmoid (41%), presence of lymphovascular invasion (57%), pT3 (65%), and pN0 (37%) ([Table 1](#T1){ref-type="table"}).

###### 

The Baseline Demographical, Histological, Clinical, and Laboratories Characteristics of All Patients in This Study

  Characteristics                                                        All patients       Patients with Stage IIA   Patients with Stage IIB   Patients with Stage IIIA   Patients with Stage IIIB   P value[\*](#t1f1){ref-type="table-fn"}
  ---------------------------------------------------------------------- ------------------ ------------------------- ------------------------- -------------------------- -------------------------- -----------------------------------------
  Patients (n)                                                           150                21                        34                        46                         49                         0.208
  Age (mean, range) (years)                                              61 (38-86)         63 (41-76)                57 (38-64)                62 (44-86)                 65 (42-81)                 0.214
  Gender (n, %)                                                                                                                                                                                       
   Male                                                                  102 (68)           13 (59)                   21 (62)                   30 (64)                    38 (67)                    0.347
   Female                                                                48 (32)            8 (41)                    13 (38)                   16 (36)                    11 (33)                    
  Smoking habits (n, %)                                                                                                                                                                               
   Presence                                                              100 (67)           15 (68)                   22 (64)                   31 (67)                    32 (69)                    0.146
   Absence                                                               50 (33)            6 (32)                    12 (36)                   15 (33)                    17 (31)                    
  Weight loss (n, %)                                                                                                                                                                                  
   Presence                                                              81 (54)            11 (52)                   18 (53)                   25 (55)                    27 (57)                    0.206
   Absence                                                               69 (46)            10 (48)                   16 (47)                   21 (45)                    22 (43)                    
  Tumor grade (n, %)                                                                                                                                                                                  
  Grade 1                                                                31 (21)            10 (47)                   2 (6)                     11 (24)                    8 (17)                     0.097
  Grade 2                                                                86 (57)            7 (31)                    21 (62)                   27 (59)                    31 (63)                    
  Grade 3                                                                33 (22)            4 (22)                    11 (32)                   8 (17)                     10 (20)                    
  Localization of primary tumor (n, %)                                                                                                                                                                
   Caecum and right colon                                                26 (17)            3 (14)                    4 (11)                    5 (11)                     14 (29)                    
   Transverse colon                                                      31 (21)            4 (19)                    5 (15)                    7 (15)                     15 (31)                    0.128
   Left colon and recto-sigmoid region                                   62 (41)            9 (43)                    19 (56)                   26 (57)                    8 (15)                     
   Rectum                                                                31 (21)            5 (24)                    6 (18)                    8 (17)                     12 (25)                    
  Lymphovascular invasion (n, %)                                                                                                                                                                      
   Absence                                                               65 (43)            14 (67)                   26 (76)                   17 (37)                    8 (16)                     0.047[\*](#t1f1){ref-type="table-fn"}
   Presence                                                              85 (57)            7 (33)                    8 (24)                    29 (63)                    41 (84)                    
  Primary tumor size (mean, range)                                       3.4 (0.9-6.1)      1.1 (0.9-1.4)             3.4 (1.9-6.1)             2.8 (1.7-5.6)              3.5 (1.7-5.7)              0.146
  Nodal involvement (n, %)                                                                                                                                                                            
   N0                                                                    55 (37)            21 (100)                  34 (100)                  0                          0                          
   N1                                                                    10 (6)             0                         0                         4 (9)                      6 (12)                     0.157
   N2                                                                    40 (27)            0                         0                         18 (39)                    22 (45)                    
   N3                                                                    45 (30)            0                         0                         24 (52)                    21 (43)                    
  pT (n, %)                                                                                                                                                                                           
   pT1                                                                   3 (2)              3 (14)                    0                         0                          0                          
   pT2                                                                   18 (12)            18 (86)                   0                         0                          0                          0.109
   pT3                                                                   97 (65)            0                         28 (82)                   35 (76)                    34 (70)                    
   pT4                                                                   32 (21)            0                         6 (18)                    11 (14)                    15 (30)                    
  Neoadjuvant treatment for 31 patients with rectum cancer (n, %)                                                                                                                                     
   Absence                                                               14 (45)            5 (100)                   2 (33)                    4 (50)                     7 (58)                     0.185
   Neoadjuvant radio-chemotherapy                                        17 (55)            0                         4 (67)                    4 (50)                     5 (42)                     
  Adjuvant treatment for all of patients (n, %)                                                                                                                                                       
  Absence                                                                34 (23)            21 (100)                  9 (27)                    2 (4)                      2 (5)                      
  Adjuvant radiotherapy                                                  8 (5)              0                         2 (6)                     3 (7)                      3 (6)                      0.137
  Adjuvant radio-chemotherapy                                            2 (1)              0                         0                         1 (2)                      1(2)                       
  MAYO regimen                                                           8 (5)              0                         3 (9)                     3 (7)                      2 (5)                      
  DeGraumont regimen                                                     19 (13)            0                         19 (56)                   0                          0                          
  FOLFOX4                                                                36 (24)            0                         1 (2)                     19 (41)                    16 (33)                    
  mFOLFOX6                                                               43 (29             0                         0                         18 (39)                    34 (69)                    
  Recurrence rate (%)                                                    78                 14                        68                        91                         100                        0.014[\*](#t1f1){ref-type="table-fn"}
  First site of metastasis (n, %)                                                                                                                                                                     
   No metastasis                                                         33 (22)            18 (86)                   11 (32)                   4 (8)                      0 (0)                      
   Liver                                                                 23 (15)            0                         3 (9)                     9 (20)                     11 (23)                    
   Bone                                                                  8 (6)              0                         2 (6)                     3 (6)                      3 (6)                      0.037[\*](#t1f1){ref-type="table-fn"}
   Lung                                                                  17 (11)            0                         2 (6)                     8 (18)                     7 (14)                     
   Peritoneum                                                            18 (12)            3 (14)                    6 (18)                    7 (15)                     2 (4)                      
   Brain                                                                 14 (9)             0                         1 (2)                     8 (18)                     5 (10)                     
   Multiple sites                                                        37 (25)            0                         9 (27)                    7 (15)                     21 (43)                    
  Baseline leukocyte count (x10^9^)                                      9.7±7.2            6.4±4.3                   6.7±4.2                   8.1±3.9                    9.2±6.8                    0.034[\*](#t1f1){ref-type="table-fn"}
  Baseline neutrophils count (x10^9^)                                    5.8±2.1            4.4±1.3                   4.7±1.6                   5.4±1.9                    5.6±2.3                    0.041[\*](#t1f1){ref-type="table-fn"}
  Baseline platelet count (x10^9^)                                       499 ± 112          424±98                    446±94                    465±97                     498±114                    0.036[\*](#t1f1){ref-type="table-fn"}
  Baseline hemoglobin level (g/dl)                                       9.8±2.8            9.7±2.1                   9.5±2.6                   9.6±2.9                    9.4±2.7                    0.264
  Baseline serum uric acid level (mg/dL)                                 9.67±4.87          5.64±1.78                 6.44±2.46                 7.98±2.59                  9.46±5.21                  0.024[\*](#t1f1){ref-type="table-fn"}
  Baseline serum LDH level (U/L)                                         368.4±98.5         345.2±94.4                358.3±91.4                354.6±94.3                 367.8±98.9                 0.064
  Serum CEA level (ng/mL)                                                11.4±9.7           1.94±0.58                 1.96±0.89                 5.6±4.3                    11.2±6.8                   0.042[\*](#t1f1){ref-type="table-fn"}
  Serum CA 19.9 level (U/mL)                                             112.4±84.7         21.6±6.8                  24.9±7.4                  48.9±24.9                  119.25±86.2                0.038[\*](#t1f1){ref-type="table-fn"}
  Follow-up period (months)(mean, range)                                 61 (18-65)                                                                                                                   
  Estimated disease-free survival rates (95% CI; number still at risk)                      86 (32-92)                79 (24-82)                57 (18-76)                 38 (16-47)                 0.036[\*](#t1f1){ref-type="table-fn"}
   1-year rates                                                          89 (51-100; 150)   100 (100-100; 21)         100 (100-100; 34)         95 (86-100; 46)            75 (51-100; 49)            
   3-year rates                                                          64 (34-100; 98)    95 (93-100; 20)           89 (81-100; 32)           74 (69-100; 30)            42 (34-100; 16)            0.015[\*](#t1f1){ref-type="table-fn"}
   5-year rates                                                          48 (0-100; 33)     86 (81-100; 18)           71 (68-100; 11)           59 (54-100;                N/A                        
  Last situation (n, %)                                                                                                                                                                               
   Live                                                                  98 (65)            20 (95)                   31 (91)                   24 (52)                    23 (47)                    
   Death                                                                 52 (35)            1 (5)                     3 (9)                     22 (48)                    26 (53)                    0.032[\*](#t1f1){ref-type="table-fn"}

A two tailed p value of \<0.05 was considered statistically significant

Median follow-up time was 98 (range 9-98) months and the proportion of patients who did not relapse was 22%. The first area of metastasis was multiple (25 %) among metastatic patients. Based on the analyses, patients were stratified according to quartiles of serum uric acid with cutoff values defined as \<3.98 mg/dL (lowest quartile, Group 1), 3.99-5.96 mg/dL (Group 2), 5.97-8.36 mg/dL (Group 3), and \>8.37mg/dL (highest quartile, Group 4) ([Table 2](#T2){ref-type="table"}).

###### 

Comparison of Characteristics of Demographical, Histological, and Clinical and Analyses of Survival According to the Divided the Level of Serum Uric Acid

  Characteristics                               Group 1 (\<3.98)   Group 2 (3.99-5.96)   Group 3 (5.97-8.36)   Group 4 (\>8.37)   P[\*](#t2f1){ref-type="table-fn"}
  --------------------------------------------- ------------------ --------------------- --------------------- ------------------ ---------------------------------------
  Patients (n)                                  28                 39                    49                    34                 0.114
  Age (mean, range) (years)                     64 (41-78)         52 (38-64)            61 (38-83)            66 (43-86)         0.218
  Gender (n, %)                                                                                                                   0.094
   Male                                         19 (68)            21 (54)               36 (74)               26 (77)            
   Female                                       9 (32)             18 (46)               13 (26)               8 (23)             
  Smoking habits (n, %)                                                                                                           0.116
   Presence                                     14 (50)            23 (60)               36 (73)               27 (79)            
   Absence                                      14 (50)            16 (40)               13 (27)               7 (21)             
  Clinical stage by TNM (n, %)                                                                                                    0.031[\*](#t2f1){ref-type="table-fn"}
   Stage IIA                                    13 (46)            5 (12)                2 (4)                 1 (3)              
   Stage IIB                                    7 (25)             14 (36)               11 (22)               2 (6)              
   Stage IIIA                                   5 (18)             12 (31)               14 (29)               15 (44)            
   Stage IIIB                                   3 (11)             8 (21)                22 (45)               16 (47)            
  Tumor grade (n, %)                                                                                                              0.048[\*](#t2f1){ref-type="table-fn"}
   Grade 1                                      19 (69)            10 (26)               2 (4)                 0 (0)              
   Grade 2                                      6 (21)             24 (62)               34 (69)               22 (65)            
   Grade 3                                      3 (10)             5 (12)                13 (27)               12 (35)            
  Localization of primary tumor (n, %)                                                                                            0.168
   Caecum and right colon                       6 (21)             9 (23)                5 (11)                6 (18)             
   Transverse colon                             8 (29)             10 (26)               7 (14)                6 (18)             
   Left colon and recto-sigmoid region          10 (36)            12 (31)               30 (61)               10 (29)            
   Rectum                                       4 (14)             8 (20)                7 (14)                12 (35)            
  Lymphovascular invasion (n, %)                                                                                                  0.037[\*](#t2f1){ref-type="table-fn"}
   Absence                                      21 (75)            19 (49)               14 (29)               11 (32)            
   Presence                                     7 (25)             20 (51)               35 (71)               23 (68)            
  Primary tumor size (mean, range) (cm)         1.1 (0.9-1.8)      2.4 (1.9-3.1)         3.5 (2.1-4.6)         3.9 (2.8-5.7)      0.107
  Nodal involvement (n, %)                                                                                                        0.047[\*](#t2f1){ref-type="table-fn"}
   N0                                           18 (64)            31 (80)               6 (12)                0 ()               
   N1                                           8 (29)             2 (5)                 0 ()                  0 ()               
   N2                                           2 (7)              5 (13)                16 (33)               17 (50)            
   N3                                           0 ()               1 (2)                 27 (55)               17 (50)            
  pT2 (n, %)                                                                                                                      0.141
   pT1                                          2 (6)              1 (3)                 0 ()                  0 ()               
   pT2                                          15 (54)            2 (5)                 1 (1)                 0 ()               
   pT3                                          8 (29)             30 (77)               36 (75)               23 (68)            
   pT4                                          3 (11)             6 (15)                12 (24)               11 (32)            
  First site of metastasis (n, %)                                                                                                 0.027[\*](#t2f1){ref-type="table-fn"}
   No metastasis                                18 (64)            13 (33)               2 (5)                 0 (0)              
   Liver                                        3 (11)             3 (7)                 7 (14)                10 (29)            
   Bone                                         2 (8)              3 (7)                 3 (6)                 0 (0)              
   Lung                                         1 (3)              4 (10)                5 (10)                7 (21)             
   Peritoneum                                   1 (3)              4 (10)                8 (16)                5 (15)             
   Brain                                        0 ()               1 (5)                 5 (10)                8 (24)             
   Multiple sites                               3 (11)             11 (28)               19 (39)               4 (11)             
  Baseline leukocyte count (x10^9^)             8.7±2.8            9.1±3.1               9.8±4.1               9.9±6.4            0.204
  Baseline neutrophils count (x10^9^)           5.1±2.1            5.4±2.1               5.5±1.8               5.7±2.6            0.311
  Baseline platelet count (x10^9^)              429±91             444±98                501±101               504±113            0.043[\*](#t2f1){ref-type="table-fn"}
  Baseline hemoglobin level (g/dl)              9.8±3.4            9.6±3.1               9.5±2.1               9.2±1.9            0.098
  Baseline serum LDH level (U/L)                341.8±89.4         348±91.3              361±95.7              369±96.3           0.144
  Serum CEA level (ng/mL)                       3.6±1.4            4.7±2.5               7.8±4.1               8.6±3.8            0.034[\*](#t2f1){ref-type="table-fn"}
  Serum CA 19.9 level (U/mL)                    17.4±8.4           34.7±11.2             74.8±19.7             121.4±74.9         0.026[\*](#t2f1){ref-type="table-fn"}
  Disease-free survival (months, mean, range)   88 (78-98)         86 (77-96)            59 (21-74)            34 (16-39)         0.009[\*](#t2f1){ref-type="table-fn"}
  Last situation (n, %)                                                                                                           0.024[\*](#t2f1){ref-type="table-fn"}
   Live                                         27 (96)            32 (82)               28 (57)               11 (32)            
   Death                                        1 (4)              7 (18)                21 (43)               23 (68)            

A two tailed p value of \<0.05 was considered statistically significant

It was determined that increased serum uric acid level was significantly positively correlated with stage IIA and stage IIIB (r=0.598, p=0.029), N3 disease, (r=0.618, p=0.024), grade III tumor (r=0.631, p=0.029), presence of weight loss (r=0.539, p=0.037), presence of lymphovascular invasion (r=0.621, p=0.031), recurrence with liver metastases (r=0.648, p=0.018), baseline platelet counts (r=0.496, p=0.042), baseline CEA levels (r=0.509, p=0.036), baseline CA19-9 levels (r=0.645, p=0.028), and a shorter disease-free survival rates (r=0.651, p=0.018).

Patients with serum uric acid levels over 8.37 mg/dL had a worst prognosis, illustrated as short progression-free survival compared to other groups ([Table 2](#T2){ref-type="table"}).

The univariate analysis conducted with models which prepared for disease-free survival yielded that serum uric acid level (Odds ratio (OR) with 95% Confidential Interval (CI) 3.41 (1.45-3.56), p=0.025), stage IIA and stage IIIB (2.45 (1.54-3.42), p=0.034 and 1.86 (1.14-3.17), p=0.032, respectively), grade III tumor (3.24 (2.18-4.34), p=0.027), presence of lymphovascular invasion (2.84 (1.91-3.76), p=0.036), N disease (3.11 (1.69-3.28), p=0.039), baseline platelet (2.41 (2.04-6.32), p=0.024), and leukocyte counts (2.48 (1.97-3.84), p=0.035) had prognostic value. Multivariate analysis showed that serum uric acid level (2.86 (1.14-5.94), p=0.023) and presence of Lymphovascular invasion (3.18 (2.09-4.93), p=0.024) were independent prognostic factors.

Discussion {#sec1-4}
==========

In this cross-sectional study we investigated serum UA levels that measured at the time of diagnosis whether the effects of cancer-related events in total 150 stage II and III colorectal cancer patients. We determined that the patients included in our study who had serum UA levels over 8.37 mg/dL, metastases have developed in a shorter time and first metastatic area was liver.

Increased serum UA level was first supposed to have a possible protective effect against developing of cancer among mankind by Ames et al., (1981). This hypothesis was based on the knowledges that lipid peroxidation is inhibited and the free oxygen radicals are cleared through xanthine oxidoreductase when UA is in levels with high concentrations. (Tanriverdi et al., 2014). However, in some recent studies, antioxidants have been reported to act as prooxidants in certain cases (Giavonnucci, 2007; Petersson et al., 1983; Petersson et al., 1984; Shin et al., 2006). Especially in studies conducted on cardiovascular diseases, uric acid has been shown to act as an antioxidant in early stages of atherosclerosis but may also contribute to the pro-inflammatory effects in later stages (Ames et al., 1981; Rose et al., 2007; Tanriverdi et al., 2014). When all these results are considered, the role of uric acid in cancer biology can be assumed to be more complicated than that can be explained with its common antioxidant features.

The association between serum UA level and cancer has not been clarified yet and studies on this matter are highly limited (Ames et al., 1981). Several studies have demonstrated that premature cancer mortality rates increased significantly in both genders when urate level, a dominant monosodium form of uric acid in physiological pH, were high (Ames et al., 1981; Rose et al., 2007; Tanriverdi et al., 2014). In other studies analyzing all types of cancer, serum uric acid level was demonstrated to have a significant epidemiologic association with age, gender, and increased mortality (Ames et al., 1981; Rose et al., 2007; Tanriverdi et al., 2014). Moreover, this association may also be assumed to be affected by conditions related to increased serum UA levels such as diabetes, cardiovascular diseases, metabolic syndrome, gout, obesity, insulin resistance, alcoholism, and diet (Ames et al., 1981; Rose et al., 2007; Tanriverdi et al., 2014). Many studies have proven that obesity and metabolic syndrome, co-morbidities associated with serum UA level, are significant prognostic factors especially for breast cancer and that they are associated with reduced survival and increased mortality rate (Ames et al., 1981; Petersson et al., 1984). In this study, we excluded such conditions by defining them among the exclusion criteria.

Prior studies have shown that reduced or absent XOR in tumor cells was significantly associated with poor clinical prognosis and reduced survival in breast, stomach, colorectal, ovarian, and NSCLC cancers (Abdel-Salam et al., 2011; Ames et al., 1981; Bozkir et al., 1999; Lawol et al., 2012; Strasak et al., 2007; Rose et al., 2007; Tanriverdi et al., 2014). As a result of these studies, XOR activity was reported to be reduced in highly aggressive tumor cells and that this condition is associated with both carcinogenesis and metastasis as much as it is with the unexpected impacts on the cell differentiation (Ames et al., 1981; Tanriverdi et al., 2014).

In conclusion, the association between serum UA level and poor prognosis and increased mortality among cancer patients is not clear and a study about colorectal cancer has not been demonstrated. However several of the prior studies reported that the significant increase in serum UA levels in some cancer patients may be associated with the malignant process itself and that the high mortality rate is associated with aggressive cancers where increased nucleic acid turnover is observed (Ames et al., 1981; Rose et al., 2007; Tanriverdi et al., 2014).

The relatively small sample size and the analysis of overall survival has not been made because of not enough data for statistical analysis of all groups in our study may cause limitations. Even so we can conclude that in stage IIIA/ IIIB colorectal cancer patients, who have high serum UA levels, may develop early metastases independent of all the variables.
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